AIM ImmunoTech Inc.
AIMNYSEHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $88,000 | $170,000 | $202,000 | $141,000 | $135,000 | $163,000 |
| Operating income | −$11.7M | −$19.8M | −$31.9M | −$19.9M | −$18.8M | −$15.2M |
| Net income | −$14.0M | −$17.3M | −$29.0M | −$19.4M | −$19.1M | −$14.4M |
| Total assets | $5.8M | $8.6M | $19.4M | $40.5M | $57.7M | $64.6M |
| Total liabilities | $15.6M | $9.9M | $9.1M | $2.0M | — | — |
| Equity | −$9.8M | −$1.3M | $10.2M | $38.5M | $56.9M | $61.3M |
| EPS (diluted) | $-8.62 | $-0.31 | $-0.60 | $-0.40 | $-0.40 | — |
| Shares out. | 72.3M | 49.9M | 48.4M | 48.0M | 47.8M | 27.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −13254.5%
- Net margin
- −15861.4%
- Return on equity
- 142.7%
- Return on assets
- −241.4%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 269.2%
- Debt / equity
- —
- Book value / share
- $-0.14
- Revenue growth (YoY)
- −48.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -266.06distress
- Accruals / assets
- −51.9%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 17, 2025
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Intracoastal Capital, LlcPassive (13G)May 27, 2026
- Orca Capital AgPassive (13G)May 12, 2026
- Armistice Capital, LlcPassive (13G)Feb 14, 2025
- Deutsch ToddActivist (13D)Dec 23, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 137,078 | 1.0 | -54.8% |
| Apr 30, 2026 | 303,165 | 1.2 | +21.9% |
| Apr 15, 2026 | 248,631 | 1.0 | +55.7% |
| Mar 31, 2026 | 159,719 | 1.0 | +4.2% |
| Mar 13, 2026 | 153,264 | 1.0 | +62.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Unregistered equity sale · Other material eventMay 21, 2026
- Entered a material agreement · Results of operations · New financial obligation · Regulation FD disclosureMay 19, 2026
- Regulation FD disclosureMay 14, 2026
- Unregistered equity saleMay 12, 2026
- Entered a material agreement · Unregistered equity saleMay 8, 2026
- Entered a material agreementApr 10, 2026
- Entered a material agreement · Modified shareholder rights · Amended charter or bylaws · Other material eventMar 6, 2026
- Regulation FD disclosure · Other material eventFeb 5, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.